<DOC>
	<DOCNO>NCT00005989</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness R115777 treat patient recurrent metastatic non-small cell lung cancer .</brief_summary>
	<brief_title>R115777 Treating Patients With Recurrent Metastatic Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Assess response rate patient recurrent metastatic non-small cell lung cancer treat tipifarnib . - Determine clinical toxicity treatment patient . - Assess overall survival time progression patient population treat regimen . - Evaluate inhibition protein farnesylation vivo correlate inhibition plasma level tipifarnib . - Evaluate occurrence CYP450 polymorphisms relate drug toxicity , pharmacokinetics , response treatment patient population . OUTLINE : This multicenter study . Patients receive oral tipifarnib twice daily day 1-21 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients follow every 3 month 5 year . PROJECTED ACCRUAL : A total 50 patient accrue study 12 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm recurrent metastatic nonsmall cell lung cancer ( NSCLC ) Measurable disease At least 20 mm least one dimension Nonmeasurable define follow : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion No CNS metastases PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 12 week Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 2 time upper limit normal ( ULN ) AST great 3 time ULN ( great 5 time ULN case hepatic metastasis ) Renal Creatinine great 2 time ULN Cardiovascular No New York Heart Association class III IV heart disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled infection No prior malignancy past 5 year except adequately treat basal cell squamous cell skin cancer adequately treat noninvasive carcinoma No concurrent severe underlying disease PRIOR CONCURRENT THERAPY : Biologic therapy No prior biologic , gene , immunotherapy Chemotherapy No prior chemotherapy NSCLC except low dose cisplatin radiosensitizer Endocrine therapy Not specify Radiotherapy Prior radiotherapy le 25 % bone marrow allow Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>